There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Decibel Cannabis Company (DBCCF – Research Report) and Sutro Biopharma (STRO – Research Report) with bullish sentiments.
Decibel Cannabis Company (DBCCF)
Haywood analyst Neal Gilmer reiterated a Buy rating on Decibel Cannabis Company today and set a price target of $0.40. The company’s shares closed last Thursday at $0.10.
According to TipRanks.com, Gilmer is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Decibel Cannabis Company has an analyst consensus of Moderate Buy, with a price target consensus of $0.40.
See the top stocks recommended by analysts >>
Sutro Biopharma (STRO)
In a report released today, Boris Peaker from TD Cowen maintained a Buy rating on Sutro Biopharma. The company’s shares closed last Thursday at $2.37, close to its 52-week low of $2.01.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of
Currently, the analyst consensus on Sutro Biopharma is a Strong Buy with an average price target of $13.40, representing a 449.2% upside. In a report issued on November 8, Deutsche Bank also initiated coverage with a Buy rating on the stock with a $12.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on DBCCF:
